Thus, increasing our knowledge of TAAR1 and its ability to modulate monoaminergic and glutamatergic circuits is not only important for the development of future TAAR1 agonists and their potential therapeutic effects, but possibly also to our understanding of the pathophysiology of schizophrenia. This evidence concerns the gene TAAR1 and schizophrenia.